ArticleImmunology2007
Expression of 5-lipoxygenase (5-LOX) in T lymphocytes.
Article in Immunology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 37 citations in OpenAlex.
- Functional analysis of 5-lipoxygenase promoter repeat variants.Human molecular genetics · 2009Trial
- Metabolic pathways of eicosanoids-derivatives of arachidonic acid and their significance in skin.Cellular & molecular biology letters · 2025Review
- Association Between Genetically Elevated Omega-3 Polyunsaturated Fatty Acids and Skin Disease Risk: A Mendelian Randomization Study.Clinical, cosmetic and investigational dermatology · 2025Article
- Article
- Novel lipid mediator 7Frontiers in cell and developmental biology · 2024Article
- Eicosapentaenoic Acid Influences the Lipid Profile of an In Vitro Psoriatic Skin Model Produced with T Cells.Biomolecules · 2023Article
- The role of macrophages phenotypes in the activation of resolution pathways within human granulosa cells.Reproductive biology and endocrinology : RB&E · 2022Article
- Current knowledge of the implication of lipid mediators in psoriasis.Frontiers in immunology · 2022Review
- The interaction between ferroptosis and lipid metabolism in cancer.Signal transduction and targeted therapy · 2020Review
- Elevated Levels of Anti-Inflammatory Eicosanoids and Monocyte Heterogeneity inFrontiers in immunology · 2020Article
- Dormant 5-lipoxygenase in inflammatory macrophages is triggered by exogenous arachidonic acid.Scientific reports · 2017Article
- HTLV-1-induced leukotriene B4 secretion by T cells promotes T cell recruitment and virus propagation.Nature communications · 2017Article
- Cross-Talk between Cancer Cells and the Tumour Microenvironment: The Role of the 5-Lipoxygenase Pathway.International journal of molecular sciences · 2017Review
- Identification and Characterization of a New Protein Isoform of Human 5-Lipoxygenase.PloS one · 2016Article
- T cell lipid peroxidation induces ferroptosis and prevents immunity to infection.The Journal of experimental medicine · 2015Article
- Polyunsaturated Fatty Acid-derived lipid mediators and T cell function.Frontiers in immunology · 2014Review
- Proinflammatory and immunoregulatory roles of eicosanoids in T cells.Frontiers in immunology · 2013Article
- Dihydroceramide accumulation and reactive oxygen species are distinct and nonessential events in 4-HPR-mediated leukemia cell death.Biochemistry and cell biology = Biochimie et biologie cellulaire · 2012Article
- 5-Lipoxygenase-mediated endogenous DNA damage.The Journal of biological chemistry · 2009Article
- High expression of 5-lipoxygenase in normal and malignant mantle zone B lymphocytes.BMC immunology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
5-Lipoxygenase (5-LOX) is the key enzyme responsible for the synthesis of the biologically active leukotrienes. Its presence has been reported in cells of the myeloid lineage and B lymphocytes but has not been formally defined in T lymphocytes. In this study, we provide evidence for 5-LOX expression on both transcriptional and translational levels in highly purified peripheral blood T cells as well as in human T lymphoblastoid cell lines (MOLT4 and Jurkat). Messenger RNA (mRNA) of 5-LOX was amplified by conventional reverse transcription-polymerase chain reaction (RT-PCR; MOLT4 and Jurkat cells) and by in situ RT-PCR (T lymphocytes). 5-LOX protein expression was confirmed by Western blot and immunofluorescence studies. 5-LOX was present primarily in the cytoplasm with some nuclear localization and was translocated to the nuclear periphery after culture in a mitosis-supporting medium. Fluorescence-activated cell sorter analysis of different T-lymphocyte populations, including CD4, CD8, CD45RO, CD45RA, T helper type 2, and T-cell receptor-alphabeta and -gammadelta expressing cells, did not identify a differential distribution of the enzyme. Purified peripheral blood T lymphocytes were incapable of synthesizing leukotrienes in the absence of exogenous arachidonic acid. Jurkat cells produced leukotriene C(4) and a small amount of leukotriene B(4) in response to CD3-CD28 cross-linking. This synthesis was abolished by two inhibitors of leukotriene synthesis, MK-886 and AA-861. The presence of 5-LOX in T lymphocytes but the absence of endogenous lipoxygenase metabolite production compared to Jurkat cells may constitute a fundamental difference between resting peripheral lymphocytes and leukaemic cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.